Insilico Medicine’s Chemistry42 Drives Discovery of Novel Chemotype Pan-KRAS Inhibitors, Reported in ACS Medicinal Chemistry Letters
In a groundbreaking advancement poised to reshape the landscape of cancer therapeutics, Insilico Medicine, a pioneering clinical-stage biotechnology firm powered ...